UNSPSC 51161573: Pranlukast hydrate

This classification denotes an anti-asthmatic agent and leukotriene antagonist with the molecular formula 2C27H23N5O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FR702N558K, chemically known as benzamide, n-(4-oxo-2-(2h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)-, hydrate (2:1), but more generally known as pranlukast hydrate, which bears US NIH Compound Identifier 5311184.

European Medicines Agency schedules pranlukast hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09998MIG. Most nations, for tariff purposes, schedule pranlukast hydrate under HS 29349990. SMILES: C1CCC(CC1)CCCCOC2CCC(CC2)C(=O)NC3CCCC4C3OC(CC4=O)C5[NH]NNN5.C1CCC(CC1)CCCCOC2CCC(CC2)C(=O)NC3CCCC4C3OC(CC4=O)C5[NH]NNN5.O.

UNSPSC 51161573 Pranlukast hydrate is a Commodity code covering a single active pharmaceutical ingredient supplied through cooperative purchasing agreements to state and local government health systems. State and local procurement under this code materializes primarily through multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and health facilities, establishing framework contracts with pharmaceutical manufacturers for generic and branded active ingredients at negotiated prices. The solicitation activity reflects a shift toward consolidated supply-chain models where manufacturers supply through authorized pharmaceutical wholesalers rather than directly to individual facilities, with vendors required to meet cGMP certification, Drug Supply Chain Security Act compliance, and strict product-information documentation including NDC codes, UPCs, and manufacturing locations. Issuing bodies include state purchasing offices and multistate cooperative alliances; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent buyer, with participating members spanning multiple states including Oregon.

The most recent opportunity is MMCAP's RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products, posted January 20, 2026, with proposals due March 26, 2026. The contract term is two years for new responders with optional MMCAP extensions, or through June 30, 2028 for incumbent vendors. Evaluation weights heavily favor price competitiveness at 75 percent, with fixed pricing, administrative compliance, EDI capability, and fee agreement each weighted at 5–10 percent. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), carry professional liability insurance of at least $2 million, and accept a 3 percent administrative fee on all contract purchases. Performance penalties of $200 to $1,500 per violation apply for reporting delays, missed onboarding, or improper class-of-trade denials. The RFP does not identify set-aside designations or disadvantaged-enterprise restrictions in available documentation. No specific award values or budget ranges are disclosed.